Neurosense Therapeutics Ltd(NRSN)

0.8358-0.0352-4.04%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Neurosense Confirms Favorable Safety and Tolerability of Primec in an Alzheimer's Phase 2 Study
  THOMSON REUTERS · 2025-12-22
  Neurosense Confirms Favorable Safety and Tolerability of Primec in an Alzheimer's Phase 2 Study
- NeuroSense Reports PrimeC Shows Favorable Safety in Alzheimer's Phase 2 Trial
  Reuters · 2025-12-22
  NeuroSense Reports PrimeC Shows Favorable Safety in Alzheimer's Phase 2 Trial
- NeuroSense Therapeutics Locks Database for Phase 2 Alzheimer's Trial with Topline Results Expected in 2026
  Reuters · 2025-12-08
  NeuroSense Therapeutics Locks Database for Phase 2 Alzheimer's Trial with Topline Results Expected in 2026
- BRIEF-Neurosense Therapeutics Ltd - Resuming Regulatory Advancement In Canada For Primec In Amyotrophic Lateral Sclerosis
  Reuters · 2025-12-04
  BRIEF-Neurosense Therapeutics Ltd - Resuming Regulatory Advancement In Canada For Primec In Amyotrophic Lateral Sclerosis
- Neurosense Therapeutics Ltd - Resuming Regulatory Advancement in Canada for Primec in Amyotrophic Lateral Sclerosis
  THOMSON REUTERS · 2025-12-04
  Neurosense Therapeutics Ltd - Resuming Regulatory Advancement in Canada for Primec in Amyotrophic Lateral Sclerosis
- Neurosense Therapeutics Ltd - Anticipates Potential Nds Submission by Mid-2026
  THOMSON REUTERS · 2025-12-04
  Neurosense Therapeutics Ltd - Anticipates Potential Nds Submission by Mid-2026
- BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, Genco
  Reuters · 2025-11-24
  BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, Genco
- BUZZ-NeuroSense rises after U.S. FDA clears late-stage ALS drug trial
  Reuters · 2025-11-24
  BUZZ-NeuroSense rises after U.S. FDA clears late-stage ALS drug trial
- Neurosense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for Primec in ALS
  THOMSON REUTERS · 2025-11-24
  Neurosense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for Primec in ALS
- FDA Clears NeuroSense Therapeutics to Launch Phase 3 Trial of PrimeC for ALS
  Reuters · 2025-11-24
  FDA Clears NeuroSense Therapeutics to Launch Phase 3 Trial of PrimeC for ALS
- NeuroSense Therapeutics Shareholders to Vote on Granting Restricted Shares to Non-Management Directors at Upcoming Meeting
  Reuters · 2025-11-21
  NeuroSense Therapeutics Shareholders to Vote on Granting Restricted Shares to Non-Management Directors at Upcoming Meeting
- NeuroSense Therapeutics to Host Investor Update Webinar
  Reuters · 2025-11-03
  NeuroSense Therapeutics to Host Investor Update Webinar
- NeuroSense files to sell 333K ordinary shares for holders
  TIPRANKS · 2025-10-29
  NeuroSense files to sell 333K ordinary shares for holders
- Neurosense Therapeutics Ltd : Noble Capital Initiates Coverage With Outperform Rating; Target Price $9
  THOMSON REUTERS · 2025-10-14
  Neurosense Therapeutics Ltd : Noble Capital Initiates Coverage With Outperform Rating; Target Price $9
- NeuroSense announces ‘positive’ results from Phase-2b PARADIGM study
  TIPRANKS · 2025-10-06
  NeuroSense announces ‘positive’ results from Phase-2b PARADIGM study
- Neurosense Therapeutics Ltd -Primec Produces Statistically Significant Reductions in Alzheimer’s Disease Biomarkers
  THOMSON REUTERS · 2025-10-06
  Neurosense Therapeutics Ltd -Primec Produces Statistically Significant Reductions in Alzheimer’s Disease Biomarkers
- NeuroSense Therapeutics Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer’s Disease Biomarkers
  Reuters · 2025-10-06
  NeuroSense Therapeutics Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer’s Disease Biomarkers
- NeuroSense Therapeutics Ltd. Held Annual General Meeting of Shareholders
  Reuters · 2025-09-25
  NeuroSense Therapeutics Ltd. Held Annual General Meeting of Shareholders
- BRIEF-Neurosense's Drug Candidate Shows Early Signals Of Benefit In Alzheimer's Patient-Derived Neurons
  Reuters · 2025-09-11
  BRIEF-Neurosense's Drug Candidate Shows Early Signals Of Benefit In Alzheimer's Patient-Derived Neurons
- NeuroSense Therapeutics Announces Positive Initial Results from Phase 2 Trial of PrimeC for Alzheimer's Disease
  Reuters · 2025-09-11
  NeuroSense Therapeutics Announces Positive Initial Results from Phase 2 Trial of PrimeC for Alzheimer's Disease
Company Profile
Company Name
Neurosense Therapeutics Ltd
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.neurosense-tx.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
- 2025-08-15
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 2025-04-07
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2025-01-16
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2025-01-06
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-12-13
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-12-09
  Beneficial Ownership Change
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
- 2024-11-22
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-11-19
  Public Prospectus
  Form F-1 - Registration statement for certain foreign private issuers
  Form F-1 - Registration statement for certain foreign private issuers
- 2024-05-21
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-05-20
  [Amend]Public Prospectus
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
- 2024-05-10
  Public Prospectus
  Form F-1 - Registration statement for certain foreign private issuers
  Form F-1 - Registration statement for certain foreign private issuers
- 2024-04-04
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2024-02-13
  Beneficial Ownership Change
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
- 2024-02-13
  Beneficial Ownership Change
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
- 2023-12-04
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence

1D
5D
Day
Week
Month

Loading ...

High

0.8800

Open

0.8800

Volume%

0.39

Low

0.8350

0.8710

T/O Rate

0.27%

To The Moon

Neurosense Therapeutics Ltd(NRSN)

Company Profile

Most Discussed